ClinicalTrials.gg
CompletedNCT00435162Updated May 9, 2011Results posted

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

A Phase 3 interventional study of Valsartan 0.25 mg/kg and Valsartan 1.0 mg/kg in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in 11 countries. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2011-05-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
6 Months to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
107th of 139
74 · median 198
Started
2007
with 11 others
Phase 3
53 of 140
none open now
Registered
75th of 140
by date
Lead sponsor
19 of 140
Novartis Pharmaceuticals

Among the 140 studies testing valsartan in Hypertension, this one is the 107th largest by enrollment of the 139 interventional ones that give a count, is one of 12 that started in 2007, is one of 53 in phase 3, and was the 75th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 6 Months to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of three doses of valsartan (0.25, 1.0, and 4.0 mg/kg) on mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) in 6 months - 5 year old children with hypertension (sitting systolic blood pressure [SSBP] ≥ 95th percentile ).

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Children
  • pediatrics
  • High Blood Pressure
  • Hypertension
  • Valsartan
04

Who can participate

Ages eligible
6 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 6 months - 5 years at Visit 1, with a documented history of hypertension
  • Must be able to swallow liquid formulation
  • Must be ≥ 6 kg or ≤ 40 kg at randomization
  • Must have documented history MSSBP (mean of 3 measurements) must be ≥ 95th percentile for age, gender and height, at randomization
  • If patients enter with uncontrolled BP they can remain on background antihypertensives with an unchanged dosing regimen
  • If patients have had a solid organ transplant more than 1 year ago they must be on stable doses of therapy
  • Parent(s)/guardian(s) are able to follow verbal and/or written instructions in the local language

Exclusion criteria

Exclusion Criteria:

  • Patients with background ARB therapy
  • Patients demonstrating any abnormalities or clinically noteworthy abnormal lab values (other than those relating to renal function)
  • /SGOT or ALT/SGPT > 3 times the upper limit of the reference range
  • \< 30 mL/min/1.73m²
  • Serum potassium > upper limit of the reference range
  • MSSBP ≥ 25% above the 95th percentile
  • Patients exhibiting clinically significant abnormalities
  • Patients that have coarctation of the aorta with a gradient of ≥ 30 mm Hg, or renal artery stenosis

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Low Dose

    Drug: Valsartan 0.25 mg/kg

  • Experimental
    Medium Dose

    Drug: Valsartan 1.0 mg/kg

  • Experimental
    High Dose

    Drug: Valsartan 4.0 mg/kg

Interventions

  • DrugValsartan 0.25 mg/kg

    Drug page: Valsartan

    once daily

  • DrugValsartan 1.0 mg/kg

    Drug page: Valsartan

    once daily

  • DrugValsartan 4.0 mg/kg

    Drug page: Valsartan

    once daily

06

What researchers measure

Primary outcomes

  1. Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6)

    Time frame: baseline and week 6

Secondary outcomes

  1. Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)to End of Period 1 (Week 6)

    Time frame: baseline and week 6

  2. Change From End of Period 1 (Week 6) in Mean Sitting Systolic Blood Pressure (MSSBP) to End of Placebo-controlled Withdrawal Period (Week 8)

    Time frame: week 6 and week 8

  3. Change From End of Period 1 (Week 6) in Mean Sitting Diastolic Blood Pressure (MSDBP) to End of Placebo-controlled Withdrawal Period (Week 8)

    Time frame: week 6 and week 8

07

Results

Posted May 9, 2011

Participant flow

At period 1, participants were randomized (2:1:2) to Valsartan 0.25 mg/kg, 1.0 mg/kg or 4.0 mg/kg. At period 2, participants were randomized (1:1) to either stay on Valsartan or switch to placebo.

Period 1 (6 Weeks)
Participant flow — Period 1 (6 Weeks)
MilestoneLow Dose in Both PeriodsLow Dose, Then PlaceboMedium Dose in Both PeriodsMedium Dose, Then PlaceboHigh Dose in Both PeriodsHigh Dose, Then Placebo
Started1515681515
Completed1515681515
Not completed000000
Period 2 (2 Weeks)
Participant flow — Period 2 (2 Weeks)
MilestoneLow Dose in Both PeriodsLow Dose, Then PlaceboMedium Dose in Both PeriodsMedium Dose, Then PlaceboHigh Dose in Both PeriodsHigh Dose, Then Placebo
Started1515681515
Completed1514681515
Not completed010000
Withdrew: Adverse event010000

Outcome measures

PrimaryChange in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6)
Time frame:
baseline and week 6
Reported as:
Mean · mm Hg
Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6)
mm HgLow DoseMedium DoseHigh Dose
Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6)-8.3 ± 10.44-10.3 ± 9.83-14.4 ± 10.93
Statistical analysis
  • Low Dose vs Medium Dose vs High Dose · Regression, Linear · p = 0.0990 · Slope: -1.05 · 95% CI -2.31 to 0.20
SecondaryChange From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)to End of Period 1 (Week 6)
Time frame:
baseline and week 6
Reported as:
Mean · mm Hg
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)to End of Period 1 (Week 6)
mm HgLow DoseMedium DoseHigh Dose
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)to End of Period 1 (Week 6)-4.7 ± 9.53-8.6 ± 12.43-6.7 ± 10.61
SecondaryChange From End of Period 1 (Week 6) in Mean Sitting Systolic Blood Pressure (MSSBP) to End of Placebo-controlled Withdrawal Period (Week 8)
Time frame:
week 6 and week 8
Reported as:
Mean · mm Hg
Change From End of Period 1 (Week 6) in Mean Sitting Systolic Blood Pressure (MSSBP) to End of Placebo-controlled Withdrawal Period (Week 8)
mm HgValsartanPlacebo
Change From End of Period 1 (Week 6) in Mean Sitting Systolic Blood Pressure (MSSBP) to End of Placebo-controlled Withdrawal Period (Week 8)2.6 ± 8.384.1 ± 9.66
SecondaryChange From End of Period 1 (Week 6) in Mean Sitting Diastolic Blood Pressure (MSDBP) to End of Placebo-controlled Withdrawal Period (Week 8)
Time frame:
week 6 and week 8
Reported as:
Mean · mm Hg
Change From End of Period 1 (Week 6) in Mean Sitting Diastolic Blood Pressure (MSDBP) to End of Placebo-controlled Withdrawal Period (Week 8)
mm HgValsartanPlacebo
Change From End of Period 1 (Week 6) in Mean Sitting Diastolic Blood Pressure (MSDBP) to End of Placebo-controlled Withdrawal Period (Week 8)1.8 ± 8.993.4 ± 8.74

Adverse events

Collected over Period 1 (Baseline to Week 6) and Period 2 (Week 6 to Week 8). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose in Both Periods—1/15 (6.7%)8/15 (53.3%)
Low Dose, Then Placebo—0/15 (0%)10/15 (66.7%)
Medium Dose in Both Periods—0/6 (0%)3/6 (50%)
Medium Dose, Then Placebo—1/8 (12.5%)4/8 (50%)
High Dose in Both Periods—0/15 (0%)9/15 (60%)
High Dose, Then Placebo—2/15 (13.3%)11/15 (73.3%)
Most frequent serious events
Most frequent serious events
EventLow Dose in Both PeriodsLow Dose, Then PlaceboMedium Dose in Both PeriodsMedium Dose, Then PlaceboHigh Dose in Both PeriodsHigh Dose, Then Placebo
BronchospasmRespiratory, thoracic and mediastinal disorders0/150/150/61/80/150/15
EnteritisGastrointestinal disorders0/150/150/60/80/151/15
GastritisGastrointestinal disorders1/150/150/60/80/150/15
Respiratory tract infectionInfections and infestations1/150/150/60/80/150/15
Upper respiratory tract infectionInfections and infestations1/150/150/60/80/151/15
DehydrationMetabolism and nutrition disorders0/150/150/60/80/151/15
Nephrotic syndromeRenal and urinary disorders1/150/150/60/80/151/15
Most frequent other events
Showing 10 of 40
Most frequent other events
EventLow Dose in Both PeriodsLow Dose, Then PlaceboMedium Dose in Both PeriodsMedium Dose, Then PlaceboHigh Dose in Both PeriodsHigh Dose, Then Placebo
VomitingGastrointestinal disorders3/150/151/60/80/151/15
PyrexiaGeneral disorders0/150/150/60/82/153/15
Upper respiratory tract infectionInfections and infestations1/153/150/60/80/152/15
ConstipationGastrointestinal disorders0/150/151/60/80/150/15
NasopharyngitisInfections and infestations2/151/151/60/80/150/15
Abdominal painGastrointestinal disorders1/152/150/60/82/151/15
DiarrhoeaGastrointestinal disorders0/151/150/60/82/152/15
HyperkalaemiaMetabolism and nutrition disorders0/150/150/60/82/151/15
CoughRespiratory, thoracic and mediastinal disorders1/150/150/61/82/150/15
OtorrhoeaEar and labyrinth disorders0/150/150/61/80/150/15

Baseline characteristics

Age Continuous
Age Continuous(years)Low DoseMedium DoseHigh DoseTotal
Mean3.4 ± 1.283.2 ± 1.483.3 ± 1.533.3 ± 1.41
Sex: Female, Male
Sex: Female, Male(Participants)Low DoseMedium DoseHigh DoseTotal
Female134926
Male17102148
08

Study locations

11 sites
  • Sites in USA
    USA, New Jersey, United States
  • Sites in Belgium
    Belgium, Belgium
  • Sites in Brazil
    Brazil, Brazil
  • Sites in France
    Paris, France
  • Sites in Hungary
    Hungary, Hungary
  • Sites in India
    India, India
  • sites in Italy
    Italy, Italy
  • Sites in Poland
    Poland, Poland
  • Sites in South Africa
    South Africa, South Africa
  • Sites in Sweden
    Sweden, Sweden
  • Sites in Turkey
    Turkey, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 2 years 4 months after primary completion. A results delay was requested in Dec 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2007
First posted
Feb 14, 2007
Start
Mar 2007
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results delay requested
Dec 17, 2010
Results first posted
May 9, 2011
Last update
May 9, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00435162
First posted
Feb 14, 2007
Start date
Mar 2007
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
May 9, 2011
Last update
May 9, 2011

Study contacts

Novartis Pharmaceuticals
study director · Sponsor GmbH
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion